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LARYSA WICKMAN, COURTNEY HARKNESS, PETER SONG, AND DEBBIE S. GIPSON
Objective. To evaluate inpatient health care utilization for children with systemic lupus erythematosus (SLE) with and
without kidney disease.
Methods. The Healthcare Cost and Utilization Project Kids’ Inpatient Database for the years 2000, 2003, and 2006 was
used for this analysis. SLE hospitalizations from the 2006 cohort were identified and classified as those with versus
without kidney involvement by International Classification of Diseases, Ninth Revision, Clinical Modification codes.
Analyses were performed to examine determinants of hospitalization charges and changes in charges over time.
Results. In the US, 7,390 SLE-related pediatric hospitalizations generated $267 million in total charges in 2006. Of these,
4,193 discharges had kidney involvement. The average hospitalization charge was greater for SLE patients with kidney
involvement compared to those without kidney involvement ($43,100 versus $28,500; P < 0.0001). In multivariate
analysis, kidney involvement remained a significant predictor of hospitalization charges, independent of demographic
and hospital characteristics (P < 0.0001). SLE-associated acute kidney failure, transplant, and end-stage kidney disease
resulted in greater hospitalization charges than SLE without kidney involvement by $74,900 (P < 0.0001), $32,700 (P 
0.0002), and $27,400 (P < 0.0001), respectively.
Conclusion. In the US, >7,000 hospitalizations occurred in 2006 among children with SLE, with nearly 57% demon-
strating kidney involvement. Kidney involvement is a major determinant of hospitalization charges for these children.
This study represents one of the first large-scale assessments of in-hospital health care utilization by children with SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic, relaps-
ing, and remitting inflammatory autoimmune disease,
with nearly 20% of cases presenting before age 18 years
(1). Kidney involvement is present in 60–80% of pediatric
SLE cases, with 10–50% progressing to end-stage kidney
disease (ESKD) (2–10).
Studies of the adult SLE population demonstrate that
patients with kidney involvement incur substantially
higher treatment costs than those who do not have kidney
involvement (11–16). In contrast, very little data exist ex-
amining the economic burden of treating SLE in children.
A single study reported the costs of treating 119 children
with SLE in 2 tertiary pediatric rheumatology centers in
the US from 2001–2004. This study calculated the direct
inpatient and outpatient cost of childhood-onset SLE per
quality-adjusted life year to be $30,908 (17).
Given the paucity of pediatric data, we sought to further
investigate the charges for treating children with SLE. Our
primary objective was to evaluate health care utilization
charges for hospitalized pediatric SLE patients and the
relative contribution of kidney involvement to these
charges. Our secondary objective was to identify demo-
graphic and socioeconomic factors associated with SLE
hospitalization charges.
MATERIALS AND METHODS
Data source. For this analysis, we used the Healthcare
Cost and Utilization Project Kids’ Inpatient Database
(KID), which is sponsored by the US Agency for Health-
care Research and Quality. It is the only comprehensive,
all-payer health care database for children in the US. KID
data were compiled from hospitalization claims data every
3 years and reported at the level of discharge. To ensure
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an accurate representation of pediatric cases, a method of
random sampling was used to select 10% of uncompli-
cated in-hospital births and 80% of complicated in-
hospital births and other pediatric cases from each par-
ticipating hospital. The hospital discharges are sorted
by state, hospital, and diagnosis-related group. To obtain
national estimates, the Healthcare Cost and Utilization
Project (HCUP) developed weighting for hospital dis-
charge numbers based on the American Hospital Associa-
tion universe as the standard. Data in the 2006 KID were
drawn from 3,739 hospitals in 38 reporting states for chil-
dren ages 20 years. Data were drawn from 36 and 27
states for the years 2003 and 2000, respectively. For each
year, data were collected from January 1 to December 31.
Included in each discharge record were International Clas-
sification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) diagnosis and procedure codes, patient
and hospital demographics, length of stay, and hospital
charges. This data set does not provide reimbursement
data (18).
Because the KID contains deidentified data only, this
study was reviewed and deemed not regulated by the
University of Michigan Institutional Review Board.
Outcome variables of interest. The 2006 KID cohort
discharges with a primary or secondary diagnosis of SLE
(ICD-9-CM code 710.0) were identified. SLE with kidney
involvement (SLE  KI) was defined by primary or sec-
ondary ICD-9-CM codes for nephritis, chronic kidney dis-
ease, dialysis, kidney transplant, acute kidney failure
(AKF), or kidney biopsy listed on the same SLE claim
(Table 1). SLE without kidney involvement (SLE  KI) was
defined as all SLE discharges that did not fall into the
SLE  KI cohort. We chose these codes based upon a
manual review of ICD-9-CM codes and validated this se-
lection based on prior studies that utilized ICD-9-CM
codes to define lupus nephritis (12,13,15). Overall, the
selected codes were consistent with the codes used in
previously reported studies, except where the definition of
kidney involvement was expanded by including codes for
Significance & Innovations
● In systemic lupus erythematosus (SLE), kidney in-
volvement can cause significant morbidity. Adult
studies have demonstrated that care for SLE pa-
tients with kidney involvement results in signifi-
cantly greater expenditures than care for those
without kidney disease.
● This study is one of the first large-scale analyses of
pediatric health care utilization for children in the
US with SLE and kidney involvement.
● In this article, we demonstrate that kidney in-
volvement is present in 57% of children hospital-
ized with SLE. Charges for hospitalizations with
SLE-associated kidney failure are 2–3 times greater
than for SLE hospitalizations without kidney fail-
ure.
● Improved understanding of charges can help lead
to more efficient utilization of health care re-
sources for children with SLE.
Table 1. ICD-9-CM codes used to define disease subgroups*




Nephritis 580.0, 580.4, 580.8, 580.81, 580.89, 580.9, 581.0, 581.1, 581.2, 581.3, 581.8, 581.81, 581.89, 581.9,
582.0, 582.1, 582.2, 582.4, 582.8, 582.81, 582.89, 582.9, 583.0, 583.1, 583.2, 583.4, 583.6, 583.7,
583.8, 583.81, 583.89, 583.9
Chronic kidney disease 585, 585.1, 585.2, 585.3, 585.4, 283.11, 403.00, 403.10, 403.90, 404.00, 404.10, 404.90, 404.01,
404.11, 404.91, 587, 588.8, 588.9, 642.1, 642.2, 794.4
Dialysis v56.0, v56.8, v45.11, v56.1, v56.2, v56.3, v45.12, 792.5, v45.1, v56.31, v56.32
Kidney transplant v42.0, 996.81
AKF 584, 584.5, 584.6, 584.7, 584.8, 584.9
ESKD 585.5, 585.6, 585.9, 586, 403.01, 403.11, 403.91, 404.02, 404.12, 404.92, 404.03, 404.13, 404.93
Procedure codes
Dialysis 39.95, 54.98, 39.93, 39.94, 39.42, 39.27
Kidney transplant 55.69, 55.53, 55.52, 55.51, 55.54
Kidney biopsy 55.23, 55.24, 55.39, 55.21
SLE  KI Any 710.0 patient not included in SLE  KI
Kidney failure groups
SLE with transplant All kidney transplant diagnosis or procedure codes
SLE with ESKD All ESKD codes except those with a transplant code
All dialysis codes and/or dialysis procedure codes except those with transplant
SLE with AKF All AKF codes except those with transplant or ESKD codes
* ICD-9-CM  International Classification of Diseases, Ninth Revision, Clinical Modification; SLE  systemic lupus erythematosus; SLE  KI  SLE
with kidney involvement; AKF  acute kidney failure; ESKD  end-stage kidney disease; SLE  KI  SLE without kidney involvement.
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hypertension associated with kidney disease. To analyze
the effect of kidney failure, we further categorized SLE 
KI into the following groups based upon ICD-9-CM codes:
AKF, ESKD, kidney transplant, and those without kidney
failure. When AKF and ESKD codes were present on the
same claim, priority was given to ESKD. Demographic and
hospitalization data extracted included age, race, sex, in-
surance type (primary or secondary insurance was private,
public, or other), median income for patient zip code,
teaching status of each hospital, total charges, and length
of stay. The primary analysis included here focused on the
2006 cohort. Data from 2000 and 2003 were used for trend
analysis.
Statistical analysis. Frequencies and percentages were
calculated for categorical demographic data, including
age, race, sex, teaching status of hospital, patient insurance
status, and median income by patient zip code for dis-
charges, including a diagnosis of SLE. Sums, SDs, means,
and SEMs were computed for the number of discharges
and charges related to SLE. Chi-square tests and t-tests
were used to assess differences between the groups. Linear
regression models were used to assess predictors of
charges and length of stay. Independent variables included
in the models were age, race, sex, teaching status of hos-
pital, insurance status, and median income by patient zip
code. Appropriate survey weights and domain, cluster,
and stratum statements were specified in all analyses to
provide accurate national estimates and assure unbiased
variance estimates. When conducting analysis of trends in
charges over time, we converted charges from 2000 and
2003 into 2006 dollars to adjust for increases in inflation
using the Consumer Price Index for All Urban Consumers.
Consequently, all results comparing trends in charges are
shown in 2006 dollars (19). All analyses were performed
with SAS, version 9.2.
RESULTS
Demographics. In 2006, a total of 7.5 million pediatric
discharges generated cumulative charges of $96.4 billion
in the US (Table 2). SLE accounted for 7,390 discharges, of
which 4,193 (57%) had SLE  KI.
SLE-related discharges were older (P  0.0001) and
more likely to be of a minority race or ethnicity (P 
0.0001), reside in a lower-income zip code (P  0.0001),
and be female (P  0.0001) compared to non-SLE pediatric
discharges. Additionally, SLE discharges were more likely
to receive their care in a teaching hospital environment
(P  0.0001) and be covered by public insurance (P 
0.0001).
When assessing SLE discharges with and without kid-
ney involvement, SLE  KI discharges included a lower
percentage of white race (18.0% versus 29.9%; P 
0.0001), a higher percentage of males (16.3% versus
12.2%; P  0.004), and a higher percentage who received
care at a teaching hospital (85.5% versus 76.1%; P 
0.0001) when compared to SLE  KI discharges.
Table 2. Comparison of pediatric hospitalizations in the US in 2006, categorized by SLE and kidney involvement status*
Pediatric discharges Pediatric SLE discharges
Non-SLE SLE P SLE  KI SLE  KI P
Age, years
15 80.6  0.2 26.2  1.5  0.0001 27.2  1.8 24.8  1.8 0.4773
15–18 10.0  0.1 37.1  1.2 36.6  1.6 37.8  1.5
19–20 9.4  0.1 36.7  1.7 36.2  2.1 37.4  1.9
Race
White 50.9  0.8 23.0  1.6  0.0001 18.0  1.8 29.9  2.0  0.0001
African American 15.1  0.5 41.1  2.1 43.9  2.7 37.3  2.2
Hispanic 24.5  0.9 25.6  2.2 26.3  2.6 24.6  2.4
Other 9.5  0.4 10.3  1.1 11.8  1.6 8.2  1.0
Sex
Male 47.2  0.1 14.5  0.8  0.0001 16.3  1.2 12.2  0.9 0.0042
Female 52.8  0.1 85.5  0.8 83.7  1.2 87.3  0.9
Teaching status
Nonteaching 46.5  0.9 18.6  1.6  0.0001 14.5  1.6 23.9  1.9  0.0001
Teaching 53.5  0.9 81.4  1.6 85.5  1.6 76.1  1.9
Insurance status
Private 46.4  0.6 38.0  1.5  0.0001 37.0  1.9 39.4  1.8 0.4998
Public 45.5  0.6 52.6  1.5 53.5  1.9 51.5  1.9
Other 8.1  0.3 9.4  0.8 9.6  0.9 9.2  1.0
Median income by zip code
$1–37,999 29.7  0.6 35.3  1.8 0.0001 33.8  2.2 37.1  2.0 0.1984
$38,000–46,999 24.9  0.4 25.8  1.2 27.0  1.6 24.2  1.5
$47,000–61,999 23.8  0.4 20.9  1.1 21.8  1.6 19.7  1.3
$62,000 21.5  0.6 18.1  1.4 17.4  1.7 19.0  1.6
* Values are the mean  SEM percentage. Total numbers of discharges are 7,558,812 for non-SLE, 7,390 for SLE, 4,193 for SLE  KI, and 3,197 for
SLE  KI. Chi-square comparisons between non-SLE vs. SLE and SLE  KI vs. SLE  KI were made within characteristic groups. SLE  systemic lupus
erythematosus; SLE  KI  SLE with kidney involvement; SLE  KI  SLE without kidney involvement.
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Analysis of charges. Table 3 provides the mean SLE-
associated charge per discharge. Mean charges were
$43,100 for SLE  KI versus $28,500 for SLE  KI
(P  0.0001). The mean length of stay was longer with
SLE  KI compared to SLE  KI (7.1 days versus 5.5 days;
P  0.0001).
Among all SLE discharges, the following characteristics
were associated with higher charges: ages 19–20 years;
African American, Hispanic, and other races; male sex;
and discharges from a teaching hospital. Among SLE  KI
discharges, ages 19–20 years and Hispanic race were as-
sociated with higher charges. Insurance status and median
income of zip code were not associated with charges in
either group.
SLE  KI accounted for 57% of SLE discharges and 67%
of SLE total charges (Table 4). When SLE  KI discharges
were subdivided according to kidney failure status, a di-
agnosis code for AKF generated the highest mean charge
per discharge of $100,000 versus $63,700 for transplant
(P  0.004) and $58,200 for ESKD (P  0.0001). ESKD was
Table 3. 2006 pediatric charges per hospitalization for children with SLE*
All SLE SLE  KI SLE  KI
All pediatric patients with SLE 36.8  1.5 43.1  2.1 28.5  1.6
Age, years
15 35.3  3.1 36.7  4.2† 33.2  4.0
15–18 34.4  2.0‡ 40.8  2.9‡ 26.3  2.4
19–20 (reference) 40.3  2.0 50.3  3.2 27.6  1.7
Race
African American 35.3  2.3‡ 39.2  3.0 29.0  2.8
Hispanic 43.9  3.1§ 54.4  4.7† 28.9  2.6
Other 45.4  4.3† 47.4  5.6 41.5  6.3†
White (reference) 29.4  2.3 35.3  4.6 24.4  1.9
Sex
Female 35.9  1.6‡ 42.2  2.3 27.9  1.6
Male (reference) 42.5  3.3 48.0  4.6 32.9  4.0
Teaching status
Nonteaching 30.9  1.9‡ 40.1  3.6 23.5  1.7‡
Teaching (reference) 38.3  1.8 43.7  2.4 30.2  2.0
Insurance status
Private 35.0  2.1 38.4  3.0 30.9  2.7
Other 39.8  3.9 47.0  6.1 29.9  2.9
Public (reference) 37.3  1.9 45.3  2.8 26.4  1.9
Median income by zip code
$1–37,999 35.4  2.6 43.2  3.9 25.9  2.2
$38,000–46,999 37.4  2.0 43.8  3.0 27.9  2.6
$47,000–61,999 36.8  2.6 40.8  3.7 31.0  3.6
$62,000 (reference) 38.8  3.3 43.9  4.9 32.6  3.7
* Values are the mean  SEM in thousands of dollars. Within each disease category, statistical compar-
isons were performed in characteristic groups and were compared to the corresponding reference group.
SLE  systemic lupus erythematosus; SLE  KI  SLE with kidney involvement; SLE  KI  SLE without
kidney involvement.
† P  0.01.
‡ P  0.05.
§ P  0.0001.








No. of discharges 3,197 433 1,180 111 2,469
Total charges, million $ 89.3 42.5 67.2 7.0 60.9
Length of stay, mean  SEM days 5.5  0.3 13.8  1.2 9.5  0.8 6.8  0.6 4.7  0.3
No. of dialysis events 0 83 701 34 0
Charge/discharge, mean  SEM thousand $ 28.5  1.6 100.0  9.8† 58.2  4.3† 63.7  8.1† 25.0  1.6
* SLE  systemic lupus erythematosus; SLE  KI  SLE without kidney involvement; SLE  KI  SLE with kidney involvement; AKF  acute kidney
failure; ESKD  end-stage kidney disease.
† P  0.0001 for comparison of mean charge/discharge for each SLE  KI subgroup with SLE  KI.
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present in 1,180 discharges, constituting 15% of SLE and
28% of SLE  KI discharges. Charges for SLE  KI, but no
kidney failure (AKF, ESKD, or kidney transplant), were
not significantly different from charges for SLE  KI
(P  0.09).
Multivariate analysis of charges. In the multivariate
analysis of the SLE population, age, race, sex, and pres-
ence of kidney involvement were all independent pre-
dictors of charges (Table 5). Charges were greatest for
young adults ages 19–20 years, those of Hispanic and
other races, males, and discharges that included a diagno-
sis code for kidney involvement. When the analysis cohort
was restricted to SLE  KI, race, admission to a teaching
hospital, and kidney failure were independent predictors
of charges.
In the SLE population, further regression analysis of the
role of kidney failure was performed. Compared to SLE 
KI discharges, SLE with AKF generated charges that were
$74,900 more (P  0.0001), ESKD generated charges that
were $27,400 more (P  0.0001), and kidney transplant
generated charges that were $32,700 more (P  0.0002).
SLE  KI discharges without kidney failure (AKF, ESKD,
or kidney transplant) generated charges that were $5,500
less (P  0.02) than SLE  KI (data not shown).
Economic trends in hospitalization expenditures. Fig-
ure 1 shows the mean charge per discharge for general
pediatric and SLE-related pediatric discharges in 2000,
2003, and 2006, adjusted for inflation. The figure demon-
strates a rise in charges for both groups from 2000–2006,
but the fraction of SLE-related charges relative to general
pediatric charges rose over this timeframe (P  0.0001).
There was also a small, but significant, increase in the
length of stay for SLE discharges over that time period
(from 5.6 days to 6.4 days; P  0.01).
DISCUSSION
This study presents one of the first large-scale analyses of
pediatric inpatient health care charges for children with
SLE. Using the KID, we found that mean hospitalization
charges were significantly greater for children with SLE
compared to other pediatric discharges. Among pediatric
SLE discharges, the presence of kidney involvement, es-
pecially kidney failure, significantly predicted higher
charges.
A coded diagnosis of AKF was associated with the high-
est charges and longest hospitalizations among the SLE
cohort. The KID does not provide data regarding the cause
Table 5. Adjusted multivariate analysis of hospitalization charges within SLE and
SLE  KI disease subgroups*
All SLE SLE  KI
Mean  SEM P Mean  SEM P
Age, years
15 7.9  3.5 0.023 1.5  5.8 NS
15–18 8.5  2.7 0.002 2.3  4.7 NS
19–20 Reference Reference
Race
African American 4.3  3.5 NS 1.2  5.2 NS
Hispanic 13.9  4.1 0.001 18.7  6.5 0.004
Other 15.8  5.1 0.002 11.7  6.5 NS
White Reference Reference
Sex
Female 7.6  3.7 0.042 6.2  5.4 NS
Male Reference Reference
Teaching status
Nonteaching 5.0  2.9 NS 12.6  4.8 0.009
Teaching Reference Reference
Insurance status
Private 0.4  3.0 NS 1.1  4.3 NS
Other 1.1  5.1 NS 2.6  7.5 NS
Public Reference Reference
Median income by zip code
$1–37,999 5.7  4.0 NS 2.7  5.9 NS
$38,000–46,999 5.5  3.8 NS 7.3  5.8 NS
$47,000–61,999 4.5  4.0 NS 7.2  6.1 NS
$62,000 Reference Reference
Kidney involvement
SLE  KI 12.7  2.6  0.0001
SLE  KI Reference
* Values are in thousand US dollars and compared to the reference for each characteristic. SLE  systemic
lupus erythematosus; SLE  KI  SLE with kidney involvement; NS  not significant; SLE  KI  SLE
without kidney involvement.
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of AKF. Consequently, we cannot specify whether AKF
was secondary to lupus nephritis. Regardless, these results
were not surprising, since the increased charges associated
with AKF were consistent with other studies of hospital-
ized patients who develop AKF, regardless of etiology
(20,21).
While SLE with a kidney transplant represented a rela-
tively small proportion of SLE discharges (1.5%), the mean
charge per discharge associated with a kidney transplant
diagnosis was substantial and greater than SLE-associated
ESKD. Approximately 30% of transplant-related dis-
charges included the code for the kidney transplant pro-
cedure, implying that the transplant was performed during
that hospitalization. It is probable that the transplant op-
eration and postoperative care contributed significantly to
the charges for the group as a whole.
Compared to AKF and transplant, ESKD accounted for
the least expensive hospitalizations, but the greatest num-
ber of discharges and total charges. ESKD contributed to
15% of SLE discharges and generated 28% of all SLE-
associated charges. The high charges may be a combina-
tion of the high proportion of discharges and the pro-
longed length of hospital stay. At 9.5  0.8 days, this group
had the second-longest mean  SD length of stay. Analysis
of the primary reason for admission in a prospective study
may provide more insight into these hospitalizations and
potentially provide a target for reduction in health care
resource utilization.
Hospitalization for SLE  KI without kidney failure
resulted in slightly lower charges than SLE  KI. The
mean  SD length of stay was shortest for this group at
4.7  0.3 days, compared to 5.5  0.3 days for SLE  KI
and 6.8  0.6, 9.5  0.8, and 13.8  1.2 days for kidney
transplant, ESKD, and AKF, respectively. Some of the
SLE  KI without kidney failure hospitalizations may
have included brief, elective hospitalizations for diagnos-
tic and therapeutic procedures such as kidney biopsy or
medication infusion. Regardless, these data support the
hypothesis that the presence of kidney failure, not solely
kidney involvement, is the key determinant of increased
hospitalization charges for SLE patients.
We examined the relationship between demographic
and socioeconomic factors and inpatient charges, postu-
lating that factors that lead to worse disease severity will
result in greater charges. Multiple studies of patients
with SLE have shown worse generalized SLE and kidney-
related disease severity and outcomes in those of male sex,
nonwhite race, and low socioeconomic status (8,22–24).
Data also exist demonstrating that both general SLE and
kidney-related disease damage are associated with higher
direct costs in the care of patients with SLE (14,16,25).
Based on these studies, one would conclude that sex,
race, socioeconomic status, and severe kidney disease
would all significantly affect health care utilization. In our
study, this was only partially true. When examining all
SLE discharges, sex and race were associated with higher
charges in both bivariate and multivariate analyses, while
socioeconomic factors such as insurance status and me-
dian income of patient zip code were not. In SLE  KI
discharges, race was associated with higher charges on
both bivariate and multivariate analyses, whereas socio-
economic factors were not.
Our analysis only examined inpatient charges, and it is
possible that examination of outpatient expenditures
would find an association between socioeconomic status
and charges. It may be that once a patient is admitted to the
hospital, their disease has become severe enough that so-
cioeconomic differences affecting disease severity become
less important in predicting charges. It may also be that
insurance status and income by zip code are not a com-
plete reflection of the socioeconomic factors that affect
disease management and severity. Petri et al examined the
relationship between race, socioeconomic status, and mor-
bidity in SLE and found that poor scores rating patient
Figure 1. Mean charge per discharge trend data for pediatric systemic lupus erythema-
tosus (SLE) and non-SLE discharges from 2000–2006.
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compliance with the prescribed treatment regimen were
associated with kidney disease severity, while other stan-
dard measures of socioeconomic status such as income
were not directly associated with disease status (26). Data
on patient compliance were not available in the KID for
inclusion in our analysis. Another explanation may be that
the KID employs categorical data to characterize socio-
economic status and that utilization of continuous vari-
ables would reveal a linear association or threshold effect
on hospitalization charges.
It was not surprising that discharges from a teaching
hospital were associated with higher charges. Hospitaliza-
tion at a teaching hospital has traditionally been associ-
ated with higher costs and charges due to more complex
cases, specialized services, and time directed to graduate
medical education (27,28).
Prior studies have demonstrated an association between
disease severity and age at presentation. Descloux et al
examined the effect of age at disease onset on disease
severity, dividing by prepubertal (9 years), peripubertal
(9–14 years), and postpubertal (14 years), and found an
inverse relationship between age and extent of overall
disease damage regardless of disease duration, although
this relationship did not apply to renal damage specifically
(29). In our study, to analyze whether age effect translated
into higher charges, age was divided into 3 groups: 15
years to represent the pre- and peripubescent population,
15–18 years to represent the postpubescent population,
and 19–20 years to represent young adults. Initially, the
age cutoff for the youngest group was 10 years, but this
resulted in a very small sample size, precluding the ability
to make meaningful associations with this group. We also
deviated from prior publications, since this HCUP study
included prevalent and incident SLE patients with age at
hospitalization documented, not age at SLE onset.
On multivariate analysis, older age was associated with
higher charges for all SLE discharges, but this was not true
for the SLE  KI subgroup. This contradicts the presumed
hypothesis that the younger patients with more severe
disease would generate higher charges. Further analysis of
this question would require more detailed analysis than
performed here, but one could postulate that this contra-
diction may be explained by non–SLE-related factors such
as location of service (19–20-year-olds may be admitted to
adult wards), higher rates of obstetrical care in 19–20-year-
old patients, or a greater burden of SLE-associated compli-
cations in survivors of early-onset SLE. The lack of an
association on multivariate analysis for age in the SLE 
KI subgroup is consistent with past publications (by Baqi
et al and Descloux et al) that also failed to demonstrate an
association between age and development of ESKD (5,29).
One study has reviewed pediatric SLE health care utili-
zation in the past. Brunner et al evaluated SLE costs from
2 pediatric centers, examining variables such as inpatient
versus outpatient care, medications, laboratory testing,
and dialysis (17). Our analysis was different in that we
examined inpatient care only, analyzing demographic and
kidney disease–specific variables. Both the study by Brun-
ner et al and our study examined the role of dialysis/ESKD
on charges. Brunner et al examined the cost of dialysis in
their population (n  119), finding that dialysis patients
constituted 2.5% of their study population, but contrib-
uted to 11% of the total direct costs. In our study of
7,558,812 pediatric and 7,390 pediatric SLE hospitaliza-
tions in 2006, we found that ESKD contributed to 15% of
SLE discharges and 28% of all SLE-associated charges.
While the 2 analyses are not directly comparable, they
both demonstrate that ESKD is responsible for a dispro-
portionate percentage of total SLE health care resources.
Several studies have examined health care utilization by
adults with SLE on a national level and demonstrated
results consistent with our study. Pelletier et al reported
data from a 2006–2008 US claims database that adult SLE
patients with kidney involvement were hospitalized more
frequently than those without kidney involvement (30.3%
versus 13.6%; P  0.001) and had greater annual followup
costs in both inpatient and outpatient settings ($30,652
versus $12,029; P  0.001) (15). Clarke et al surveyed adult
SLE patients at 6 centers in the US, Canada, and the UK on
their reported use of medical services and calculated an
estimated cost based on market costs. They reported that
the 4-year (1995–1999) cumulative direct medical cost of
SLE patients with kidney involvement was $27,869–
99,544 versus $20,337 in those without kidney involve-
ment (16). Li et al examined a Medicaid database (com-
bined pediatric and adult data) and reported that the mean
annual cost over a 5-year period ranged from $27,463–
50,578 in patients with kidney involvement versus
$13,014–16,638 in patients without kidney involvement.
Patients that developed ESKD had mean costs ranging
from $47,660–106,982 per annum (13).
Our data indicated that the fraction of pediatric SLE
hospitalization charges compared to other pediatric hos-
pitalization charges was rising between 2000 and 2006
(P  0.0001). Consequently, we cannot attribute the rising
charges to inflation alone. Review of the data demon-
strated a small, but significant, increase in the length of
stay between 2000 and 2006 (from 5.6 days to 6.4 days).
Possible explanations may be that novel therapies targeted
for SLE are disproportionately expensive and that survival
of complex patients is increasing the length of stay.
The greatest strength of this study was the size and
scope of the KID. The use of a national claims database
offered data that eliminate single-center biases. The KID
provided sufficient data that permitted us to move beyond
demographic summaries and examine disease-specific fac-
tors such as kidney failure and its contribution to charges.
Apart from the analysis by Li et al examining the effects of
ESKD on charges reported in a Medicaid database (13), few
other studies have been able to subdivide the kidney in-
volvement population to examine this specific factor.
However, there were also limitations to using this data-
base. First, assignment of billing codes is operator depen-
dent, and therefore may be subjective. For that reason, we
kept our definition of kidney involvement broad to ensure
we included anyone who may have experienced any kid-
ney complication. We reviewed ICD-9-CM codes in other
articles to inform the codes used to define SLE and kidney
involvement in this study (12,13,15). Additionally, a sep-
arate study by Chibnik et al validated the efficacy of ICD-
9-CM codes in a Medicaid population to identify patients
with lupus nephritis (30). In the study by Chibnik et al, the
positive predictive value for a patient having lupus ne-
phritis was 88%. They required greater than two 710.0
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codes for SLE, greater than 2 nephrology visits, and greater
than 2 renal ICD-9-CM codes. Our methods were different
in that we were unable to require 2 separate encounters,
since the KID data are shown by discharge rather than by
patient. Also, the sensitivity and specificity for the pedi-
atric population in the present study, which includes all
payers, may be slightly different from the predominantly
adult Medicaid population in the study by Chibnik et al.
It is notable that ICD-9-CM codes do not distinguish
between neonatal lupus and SLE. This is complicated by
the fact that SLE can present as early as infancy. Zulian
et al summarized the clinical courses of 13 patients with
infantile SLE presenting between ages 6 and 11 months
(31). An examination of the age distribution of patients
in our cohort demonstrated 57 discharges for patients ages
3 years who were at risk for misclassification. When
these discharges were removed from the analysis, no sig-
nificant change in charges was found. Given that SLE can
present in infancy, the total number of discharges at age
3 years was so small and their impact on charges so
insignificant that all pediatric ages were included in the
analysis.
Other limitations of this data set include the fact that it
is based on the number of discharges, not the number of
patients. As a result, we cannot make conclusions on med-
ical care charges per capita. Finally, this database is lim-
ited to an analysis of inpatient charges and is not inclusive
of outpatient or emergency costs. Consequently, our ana-
lysis reflects only a portion of the full expense of managing
patients with SLE.
This study represents a step toward a better under-
standing of in-hospital health care utilization by children
with SLE and SLE-associated kidney disease. Our data
demonstrated that hospitalization of SLE patients with
kidney involvement, and more specifically kidney failure,
resulted in significant health care expenditures and higher
charges. A more detailed examination of resource utiliza-
tion for SLE patients with kidney failure in addition to an
assessment of outpatient expenditures for all aspects of
SLE would complement this study and provide a more
complete description of SLE-related health care utilization
and charges.
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